/PPCB
PPCB Stock - Propanc Biopharma, Inc.
Healthcare|BiotechnologyNASDAQ
$0.71-1.25%
$0.01 (-1.25%) • Dec 19
35
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.SELL
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.78
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PPCB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.70 – $0.72
TARGET (TP)$0.82
STOP LOSS$0.65
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.09
52W High$145.46
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-21,656 | $-17,760 | $-5,671 | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-57,278,131 | $-1,536,000 | $-1,777,000 | $-1,991,000 | $-1,812,000 |
| Net Income | $-58,923,300 | $-1,821,000 | $-2,661,000 | $-2,658,000 | $-2,026,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-14.85 | $-1420.95 | $-31268.39 | $-1119475.67 | $-800.00 |
Company Overview
Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PPCBBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.39
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | $-0.39 | — | — |
Q3 2025 | Sep 29, 2025 | — | $-0.35 | — | — |
Q2 2025 | May 15, 2025 | — | $-12.50 | — | — |
Q1 2025 | Feb 14, 2025 | — | $-32.23 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-287.82 | — | — |
Q3 2024 | Sep 30, 2024 | — | $-253.05 | — | — |
Q2 2024 | May 15, 2024 | — | $-625.00 | — | — |
Q1 2024 | Feb 20, 2024 | — | $-1875.00 | — | — |
Q4 2023 | Nov 14, 2023 | — | $-2500.00 | — | — |
Q3 2023 | Sep 28, 2023 | — | $-0.12 | — | — |
Q2 2023 | May 15, 2023 | — | $-0.42 | — | — |
Q1 2023 | Feb 9, 2023 | — | $-0.51 | — | — |
Q4 2022 | Nov 14, 2022 | — | $-1.30 | — | — |
Q3 2022 | Sep 28, 2022 | — | $-4.11 | — | — |
Q2 2022 | May 16, 2022 | — | $-624999.90 | — | — |
Q1 2022 | Feb 14, 2022 | — | $-1250000.00 | — | — |
Q4 2021 | Nov 12, 2021 | — | $-1250000.00 | — | — |
Q3 2021 | Sep 28, 2021 | — | $-55.43 | — | — |
Q2 2021 | May 14, 2021 | — | $-7499999.00 | — | — |
Q1 2021 | Feb 12, 2021 | — | $-28125000.00 | — | — |
Latest News
Propanc Biopharma Plans To Investigate Phenomenon Of "Mesenchymal Drift" To Help Unlock Chronic Disease Reversal Mechanisms
📈 PositiveBenzinga•Dec 4, 2025, 01:51 PM
Propanc Biopharma Submits Request For Foreign Filing License From Spain For Two Provisional Patents To Treat Resistant Cancer, Fibrosis
📈 PositiveBenzinga•Dec 1, 2025, 01:48 PM
Propanc Biopharma Q1 2025 EPS $(0.39) Up From $(35.97) YoY
📈 PositiveBenzinga•Nov 17, 2025, 01:54 PM
Propanc Biopharma Secures $100M Convertible Preferred Stock Deal With Hexstone To Fund Digital Asset Strategy
📈 PositiveBenzinga•Nov 10, 2025, 01:50 PM
Propanc Biopharma Plans To Acquire Digital Asset Treasury Companies That Are Trading Below Their Market Capitalization To Net Asset Value
➖ NeutralBenzinga•Nov 4, 2025, 12:21 PM
Propanc Biopharma announces up to $100M strategic financing from Hexstone Capital
📈 PositiveSeeking Alpha•Oct 15, 2025, 01:04 PM
Propanc Biopharma Secures Up To $100M Strategic Financing From Hexstone Capital Via Series C Preferred Stock
📈 PositiveBenzinga•Oct 15, 2025, 12:47 PM
Propanc Biopharma Announces Plans To Establish A $100M Or Greater Digital Asset Treasury Over The Next Year
📈 PositiveBenzinga•Oct 7, 2025, 12:52 PM
Propanc Biopharma Receives Certificate Of Grant From U.S. Patent & Trademark Office For Its Proenzyme Composition Patent
📈 PositiveBenzinga•Sep 17, 2025, 12:47 PM
Propanc Biopharma Plans $100M Ethereum Purchase To Diversify Assets And Support Growth
📈 PositiveBenzinga•Sep 2, 2025, 01:08 PM
Propanc Biopharma Highlights $30M Raised Since Inception And $18.1B Market Opportunity For PRP Pancreatic And Ovarian Cancer Therapies
📈 PositiveBenzinga•Aug 25, 2025, 11:35 AM
Propanc Biopharma shares are trading higher after the company was uplisted onto Nasdaq.
📈 PositiveBenzinga•Aug 18, 2025, 05:21 PM
Propanc Biopharma Shares Trading Following Uplisting To Nasdaq
📈 PositiveBenzinga•Aug 18, 2025, 10:25 AM
Frequently Asked Questions about PPCB
What is PPCB's current stock price?
Propanc Biopharma, Inc. (PPCB) is currently trading at $0.71 per share. The stock has moved -1.25% today.
What is the analyst price target for PPCB?
No analyst price targets are currently available for this stock.
What sector is Propanc Biopharma, Inc. in?
Propanc Biopharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PPCB's market cap?
Propanc Biopharma, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does PPCB pay dividends?
No, Propanc Biopharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLCS
Cell Source, Inc.
$0.50
Mkt Cap: $0.0B
GLABF
Gemina Laboratories Ltd.
$0.09
Mkt Cap: $0.0B
HOOK
HOOKIPA Pharma Inc.
$0.88
Mkt Cap: $0.0B
IMUC
EOM Pharmaceuticals Holdings, Inc.
$0.15
Mkt Cap: $0.0B
PRVCF
PreveCeutical Medical Inc.
$0.02
Mkt Cap: $0.0B
QPTFF
Quest PharmaTech Inc.
$0.01
Mkt Cap: $0.0B
SRBCF
Sirona Biochem Corp.
$0.01
Mkt Cap: $0.0B
SYGGF
Synairgen plc
$0.00
Mkt Cap: $0.0B
TELIF
Telescope Innovations Corp.
$0.25
Mkt Cap: $0.0B
ZHCLF
Zenith Capital Corp.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to PPCB for comparison